IntegraGen’s oncology Scientific Advisory Board (SAB) recently met at the venue of the 2016 American Society of Oncology’s (ASCO) Gastrointestinal Cancers Symposium in San Francisco to review the results from the latest clinical study exploring the predictivity of miR-31-3p on the efficacy of anti-EGFR therapy in all-RAS wild-type metastatic colorectal cancer patients. The members of IntegraGen’s oncology Scientific Advisory Board are experts on the management of patients with metastatic colorectal cancer.
IntegraGen’s analyses of the expression level of the microRNA biomarker hsa-miR-31-3p in primary tumors from all-RAS wild-type metastatic colorectal cancer patients have shown that miR-31-3p expression is predictive of the efficacy of anti-EGFR therapy in this patient population. To date the company has accumulated clinical evidence supporting the role of this biomarker from the study of 8 separate independent cohorts representing over 850 patients, including subjects enrolled in three separate, prospective, randomized controlled (level 1b evidence) studies. The clinical data the company has gathered on miR-31-3p over the past five years has demonstrated a significant robustness in findings and consistency of results from one study to another. The company’s research in this area will aid in efforts to better personalize cancer care and optimize individualized therapies for patients with metastatic colorectal cancer.
“Based on a pre-specified cut-off threshold which was replicated using prospectively collected primary tumor samples from a randomized phase III study, we have shown that patients whose primary tumors have an expression of miR-31-3p below the pre-specified threshold, obtain significantly improved benefit from anti-EGFR therapy,” stated Bernard Courtieu, CEO of IntegraGen. “We plan to present our latest data during ASCO 2016 in Chicago and continue our efforts to make a test based on the miR-31-3p biomarker available to oncologists and patients to further aid in the implementation of precision medicine strategies in the management of metastatic colorectal cancer.”
Click here for more information on IntegraGen’s efforts with miR-31-3p in metastatic colorectal cancer.